Skip to content

Janux Therapeutics JANX Cash Flow Statement

FY'25FY'24FY'23FY'22
-$113.63M-64.7%-$68.99M-18.4%-$58.29M+7.6%-$63.06M-93.0%
$2.03M-1.5%$2.06M+5.4%$1.96M+132%$841K+644%
$40.22M+21.8%$33.02M+65.1%$20.01M+16.3%$17.2M+149%
-$82.24M-87.7%-$43.81M+13.4%-$50.58M-17.8%-$42.92M-153%
$1.04M+191%$359K-80.6%$1.85M-71.3%$6.45M+335%
$59.87M+117%
$4.95M-99.3%$713.24M+1,098%$59.55M+11,810%$500K-99.9%
-$382.22M-193%$411.4M
-$83.28M-88.5%-$44.17M+15.7%-$52.43M-6.2%-$49.37M-167%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Janux Therapeutics generate?
Janux Therapeutics (JANX) generated -$77.5M in operating cash flow over the trailing twelve months.
What is Janux Therapeutics's free cash flow?
After $945.0K of capital expenditures, Janux Therapeutics's free cash flow was -$78.5M over the trailing twelve months, down 68.7% year over year.
Where does Janux Therapeutics's cash flow data come from?
Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.